Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed/refractory Hodgkin Lymphoma

This multicenter prospective phase II study examines the activity and tolerability of brentuximab vedotin as second-line therapy in patients with Hodgkin lymphoma that was relapsed or refractory after induction therapy. Brentuximab vedotin (1.8 mg/kg) was administered intravenously on day 1 of a 21-...

詳細記述

保存先:
書誌詳細
出版年:Biol Blood Marrow Transplant
主要な著者: Chen, Robert, Palmer, Joycelynne M., Martin, Peter, Tsai, Nicole, Kim, Young, Chen, Bihong T., Popplewell, Leslie, Siddiqi, Tanya, Thomas, Sandra H., Mott, Michelle, Sahebi, Firoozeh, Armenian, Saro, Leonard, John, Nademanee, Auayporn, Forman, Stephen J.
フォーマット: Artigo
言語:Inglês
出版事項: 2015
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4639410/
https://ncbi.nlm.nih.gov/pubmed/26211987
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2015.07.018
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料